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Summary This study was designed to investigate the effects of the Streptococcus
pneumoniae-derived, pro-inflammatory toxin, pneumolysin (8.37 and 41.75 ng/ml),
on the oxidative inactivation of a-1-protease inhibitor (API) by chemoattractant-
activated human neutrophils in vitro. The elastase inhibitory capacity (EIC) of API in
supernatants from unstimulated neutrophils, neutrophils treated with pneumolysin
only, or with the chemoattractant FMLP (1 mM) only, or the combination of the toxin
with FMLP was measured by a colorimetric procedure based on the activity of added
porcine elastase. The EIC of API was unaffected by exposure to pneumolysin only,
unstimulated neutrophils, or neutrophils treated with pneumolysin only. However,
exposure to FMLP-activated neutrophils resulted in a reduction of the EIC of API,
which was significantly (Po0.05) augmented by pneumolysin (mean reductions of
16%, 43% and 83% for FMLP only and in combination with 8.37 and 41.75 ng/ml
pneumolysin, respectively), and was attenuated by wortmannin (1 mM), an inhibitor
of NADPH oxidase, the oxidant-scavenger methionine (100 mM), and depletion of
Ca2þ from the cell-suspending medium. These pro-proteolytic interactions of
pneumolysin with chemoattractant-activated neutrophils may contribute to the
invasiveness of the pneumococcus.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Pneumolysin, a thiol-activated polypeptide, is one
of the best characterized virulence factors pro-
duced by the pneumococcus, possessing cytotoxic
and pro-inflammatory properties, both of which are
believed to contribute to the pathogenesis of
invasive disease.1–5 Notwithstanding the comple-
ment-activating properties of pneumolysin, the
pro-inflammatory actions of the toxin are second-
ary to plasma membrane modifications in cells such
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Ca2þ and augmentation of the production of
reactive oxidants, prostanoids, eicosanoids, cyto-
kines and chemokines both in vitro and in vivo,
1,2,6,7 all of which amplify neutrophil recruitment
to the airways.8 However, rather than eradicating
the infection, this over-exuberant inflammatory
response appears to favor persistence and extra-
pulmonary dissemination of the pneumococcus,
possibly as a consequence of damage to airway
epithelium mediated directly by pneumolysin, as
well as by reactive oxidants and proteases released
by pneumolysin-sensitized neutrophils.9–12 In addi-
tion to these mechanisms, the onslaught directed
against airway epithelium may be intensified by
hydrogen peroxide released in copious amounts by
the pneumococcus.13
There is a growing body of evidence that alpha-1-
protease inhibitor (API), a primary, albeit oxida-
tion-sensitive, inhibitor of neutrophil elastase is
critically involved in pulmonary host defenses,
protecting the lungs not only against inflammatory
insults,14 but possibly against microbial patho-
gens.15,16 This contention is supported by several
clinical studies which have reported that API
undergoes functional inactivation, both oxidative
and proteolytic, in the lungs of patients with acute
pneumonia, the magnitude of which appears to be
a determinant of unfavorable outcome.17–22
Surprisingly, given the apparent importance of
API in pulmonary host defense, the interactions
between pneumolysin, neutrophils and API have not
been described. To address this important topic,
the current study has focused on the effects of
pneumolysin alone and in combination with acti-




Recombinant pneumolysin was expressed in Escher-
ichia coli and purified from cell extracts as
previously described.23 Protein homogeneity was
confirmed by sodium dodecyl sulfate-polyacryla-
mide gel electrophoresis. The stock protein con-
centration was 0.21mg/ml, which corresponds to
1.3 106 hemolytic units/ml, and the stock was
essentially free of contaminating bacterial endo-
toxin (o2 pg/ml). The toxin was diluted in Hanks’
balanced salt solution (HBSS [pH 7.4]; 1.25mM
CaCl2; Highveld Biological Pty Ltd, Johannesburg,
South Africa) and used at fixed, final concentrations
of 8.37 and 41.75 ng/ml which we have previously
found to sensitize neutrophils for increased produc-
tion of reactive oxidants in vitro.6
Chemicals and reagents
Unless indicated all other chemicals and reagents
were obtained from the Sigma Chemical Co, St.
Louis, MO, USA.
Neutrophils
Purified neutrophils were prepared from the hepar-
inized (5U of preservative-free heparin/ml) venous
blood of healthy, non-smoking, medication-free
adult, human volunteers of average age 4072 year
and separated from mononuclear leukocytes on
Histopaque-1077 (Sigma Diagnostics) cushions at
400 g for 25min at room temperature. The resul-
tant pellet was suspended in phosphate-buffered
saline (PBS, 0.15M, pH 7.4) and sedimented with 3%
gelatin to remove most of the erythrocytes. After
centrifugation residual erythrocytes were removed
by selective lysis with 0.84% ammonium chloride at
41C for 10min.The neutrophils, which were routi-
nely of high purity (490%) and viability (495%)
determined by light microscopy and fluorescence
microscopy (exclusion of ethidium bromide) re-
spectively, were resuspended to 1 107/ml in PBS
and held on ice until used. We have previously
reported that removal of residual contaminating
cells (B- and T-lymphocytes, monocytes and natural
killer cells) by flow cytometric procedures did not
significantly affect the pro-inflammatory interac-
tions of pneumolysin with neutrophils, while these
were completely eliminated by depletion of neu-
trophils.1
Elastase inhibitory capacity (EIC) of alpha-1-
protease inhibitor (API)
Purified API (0.25mg/ml, final) was added to (i)
HBSS only (ii) neutrophils (5 106) only (iii)
neutrophilsþ pneumolysin (8.37 and 41.75 ng/ml)
(iv) neutrophilsþ the synthetic chemoattrac-
tant, N-formyl-L-methionyl-L-leucyl-L-phenylalanine
(FMLP, 1mM final) or (v) neutrophilsþ pneumolysinþ
FMLP. Neutrophils were preincubated with API for
5min at 371C prior to the addition of pneumolysin
or an equal volume of HBSS to control systems and a
further 5min incubation at 371C. This was followed
by addition of FMLP or an equal volume of HBSS to
control systems. The final volume in each tube
was 250 ml and the tubes were then incubated for
15min at 371C after which the neutrophils were
pelleted by centrifugation and the supernatants
ARTICLE IN PRESS
866 R. Cockeran et al.
harvested and assayed for EIC using a micro-
modification of a spectrophotometric procedure.24
In a preliminary series of experiments it was
established that at this concentration the API
preparation used did not interfere with either the
hemolytic activity of pneumolysin (41.75 ng/ml) or
with the toxin-mediated influx of Ca2þ into
neutrophils.6,25
Briefly, 50 ml of the supernatant were added to
250 ml of 0.2M Tris–HCl (pH 8.0) containing 21
milliunits (final) of porcine elastase and the
mixtures incubated for 15min at 371C. Following
incubation, 50 ml of the mixture was added to 150 ml
of the elastase substrate N-succinyl-L-alanyl-L-
alanyl-L-alanine-p-nitroanalide (0.6mM in Tris–
HCl) in the wells of microtiter plates and elastase
activity monitored spectrophotometrically at a
wavelength of 405 nm over a 30min time course
at 371C. The results are expressed as the magnitude
(%) of inactivation of the EIC of API.
In an additional series of experiments the effects
of inhibition of neutrophil NADPH oxidase by
wortmannin (selective inhibitor of phosphatidyli-
nositol-3-kinase, 1 mM final), as well as the reactiv-
ity of neutrophil-derived hypochlorous acid by
methionine (reactive oxidant scavenger, 100 mM),
on neutrophil-mediated inactivation of API were
investigated. These agents were added to the cells
5min prior to pneumolysin (8.37 ng/ml).
The effects of depletion of extracellular Ca2þ
were investigated by using cells suspended in
nominally Ca2þ -free HBSS containing the Ca2þ -
chelating agent, ethylene glycol-bis (b-aminoethyl
ether)-N,N,N0,N0-tetraacetic acid (EGTA, 100 mM
final) to ensure total depletion of the cation. Under
these conditions we were unable to detect influx of
Ca2þ into pneumolysin-treated neutrophils (not
shown).
Superoxide production
The effects of pneumolysin (8.37 ng/ml)7FMLP
(1 mM) in the presence and absence of wortmannin
and methionine on superoxide production by
neutrophils were measured using a lucigenin (bis-
N-methylacridinium nitrate)-enhanced chemilumi-
nescence (LECL) procedure.6 The incubation con-
ditions were as described above. LECL was
monitored over a 5min time course at 371C using
a Lumac Biocounter (Lumac Systems) following the
addition of pneumolysin7FMLP to the cells. The
final volume in each vial was 1ml HBSS supple-
mented with 0.1% bovine serum albumin, contain-
ing 0.2mM lucigenin and 1 106 neutrophils. The
results are expressed in relative light units (rlu).
Statistical analysis
The primary objective of the study was to
determine the effects of pneumolysin alone and
in combination with FMLP on neutrophil-mediated
oxidative inactivation of the EIC of API. Because of
the uneven distribution of the data, levels of
statistical significance were calculated by the
Mann–Whitney U-test (2-tailed) using GraphPad
Instatt software. All significance levels were set
to 5%. The results of each series of experiments are




As shown in Fig. 1, the EIC of API was unaffected by
pneumolysin alone (at 8.37 and 41.75 ng/ml),
neutrophils alone, or the combination of pneumo-
lysin with neutrophils. However, addition of FMLP



























































































Figure 1 Box and whisker plots of the magnitude of
inactivation of the elastase inhibitory capacity (EIC) of
alpha-1-proteinase inhibitor (API) exposed to pneumoly-
sin (Pln, 8.37 and 41.75 ng/ml) only (cell free), or to
neutrophils7pneumolysin, or to FMLP (1 mM)-activated
neutrophils7pneumolysin in Ca2þ replete and Ca2þ free
medium. Data from 5 different experiments with 5
replicates for each system in each experiment, are
expressed as the median values with 25-/75- percentiles.
*Po0.05 for comparison of the values for FMLP-activated
neutrophils in the absence of pneumolysin with the
corresponding systems in the presence of the toxin.
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cant (Po0.05) inhibition of the EIC of API which
was substantially augmented in a dose-related
manner by pre-treatment of the cells with pneu-
molysin (Po0.05 for comparison between FMLP
only and FMLPþpneumolysin at both concentra-
tions tested, as well as for comparison between the
two concentrations of pneumolysin). The inhibitory
effects of FMLP-activated neutrophils in both the
absence and presence of pneumolysin on the
EIC of API were completely attenuated by
depletion of Ca2þ from the cell-suspending med-
ium (Fig. 1).
The effects of treatment of neutrophils with
wortmannin and methionine on the inactivation of
the EIC of API following activation of the cells with
FMLP in the absence and presence of pneumolysin
(8.37 and 41.75 ng/ml) are shown in Fig. 2. These
agents significantly (Po0.05) attenuated the func-
tional inactivation of API by FMLP-activated neu-
trophils both with and without pneumolysin.
Superoxide generation
The effects of pneumolysin (8.37 ng/ml) on super-
oxide generation by FMLP-activated neutrophils in
the presence and absence of wortmannin (1 mM)
and methionine (100 mM) are shown in Fig. 3. As
reported previously,6 pneumolysin per se did not
affect the generation of superoxide by resting
neutrophils (not shown), but significantly augmen-
ted the production of the reactive oxidant by FMLP-
activated cells. Inclusion of wortmannin dramati-
cally decreased the production of superoxide by
FMLP-activated neutrophils7pneumolysin, while
methionine had no detectable effects.
Discussion
In the current study, pneumolysin, at concentra-
tions which are not cytotoxic over the time course


























































































































Figure 2 Box and whisker plots of the magnitude of
inactivation of the elastase inhibitory capacity (EIC) of
alpha-1-proteinase inhibitor (API) exposed to neutrophils
only (control), or to FMLP (1 mM)-activated neutro-
phils7pneumolysin (Pln, 8.37 and 41.75 ng/ml) in the
presence and absence of methionine (100 mM), or
wortmannin (1 mM). The data shown are those from 2
different experiments with 5 replicates for each system
in each experiment, and are expressed as the median
values with 25-/75- percentiles. *Po0.05 for comparison
of the values for FMLP-activated neutrophils in the
absence of pneumolysin with the corresponding values













































































Figure 3 Box and whisker plots of the effects of
methionine (100 mM) and wortmannin (1 mM) on FMLP
(1 mM)-activated production of superoxide by neutrophils
in the absence and presence of pneumolysin (pnl,
8.37 ng/ml). The data from 2 different experiments with
6 replicates for each system are expressed as the median
values in relative light units (rlu, background values
subtracted) with 25-/75- percentiles. *Po0.05 for com-
parison of the effects of wortmannin relative to those of
the corresponding control systems without and with
pneumolysin.
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those detected in the cerebrospinal fluid of
patients with pneumococcal meningitis,26 has been
found to sensitize human neutrophils for exagger-
ated inactivation of API on exposure of the cells to
the chemoattractant, FMLP. These pro-proteolytic
interactions of pneumolysin with neutrophils ap-
pear to be secondary to the pro-oxidative effects of
the toxin on the cells since they were associated
with augmentation of FMLP-mediated activation of
neutrophil membrane-associated oxidative meta-
bolism and attenuated by wortmannin, an inhibitor
of activation of NADPH oxidase. Methionine, which
has no inhibitory effects on NADPH oxidase, also
protected API, presumably by scavenging hypo-
chlorous acid, thereby protecting the critical
oxidation-sensitive methionine residue at position
356 of the elastase inhibitory site of API.27
The pro-oxidative interactions of pneumolysin
with neutrophils are strictly Ca2þ -dependent being
secondary to the pore-forming actions of the toxin,
which promote influx of extracellular cation and
activation or sensitization of Ca2þ -dependent pro-
inflammatory functions of the cells.6 This relation-
ship is also underscored in the current study since
depletion of Ca2þ from the cell-suspending med-
ium completely abrogated pneumolysin-mediated
enhancement of inactivation of API by FMLP-
activated neutrophils.
Because pneumolysin has been reported to
augment the release of elastase from FMLP-
activated neutrophils,6 it could be argued that
the observed decrease in the EIC of API in this
system is simply an artifact due to an excessive
amount of elastase (neutrophil-derived enzy-
meþ added porcine elastase). However, we believe
that this is unlikely to be the case. This contention
is based on the aforementioned observations that
the inactivating effects of FMLP/pneumolysin-trea-
ted neutrophils on the EIC of API were almost
completely abolished by wortmannin and methio-
nine, compatible with a predominantly pro-oxida-
tive mechanism. Nevertheless, pneumolysin-
mediated augmentation of neutrophil degranula-
tion may also contribute to free proteolytic activity
in the inflamed lung. Because of the short duration
(15min at 371C) of exposure of neutrophils to
pneumolysin in the current study, it seems unlikely
that the pro-apoptotic actions of the toxin28
contribute to its pro-proteolytic activity.
N-formylated peptides, of which FMLP is the
synthetic prototype, are crucially involved in
neutrophil mobilization from the circulation to
sites of microbial infection,29 including pneumo-
coccal infection of the airways.30 Interestingly,
neutrophils from CD38-deficient mice display an
impairment of mobilization of intracellular Ca2þ
and chemotaxis which is selective for FMLP, and fail
to accumulate in the lungs following experimental
infection with Streptococcus pneumoniae.30 These
observations underscore the relevance of the
current in vitro study using FMLP to the pathophy-
siological setting in pneumococcal disease. By
amplifying FMLP-mediated, Ca2þ -dependent sig-
naling, pneumolysin may promote an over-exuber-
ant inflammatory response in the airways,
increasing the vulnerability of respiratory epithe-
lium to elastase,31,32 which may favor extra-
pulmonary dissemination of the pneumococcus.8
This contention is strengthened by the failure of
pneumolysin to potentiate neutrophil pro-inflam-
matory responses initiated by phorbol esters,33
which are independent of Ca2þ mobilization by
these cells.34
Given that API is vulnerable to oxidative, func-
tional inactivation, and that pneumolysin interacts
pro-oxidatively with neutrophils, the results of the
current study may seem somewhat predictable.
Nevertheless, their potential significance with
respect to both immunopathogenesis of invasive
pneumococcal disease and opportunities for novel
interventions, such as the use of synthetic elastase
inhibitors, should not be under-estimated. Indeed,
this mechanism of augmentation of phagocyte-
mediated inactivation of API may also be applicable
to other infectious diseases caused by microbial
pathogens which, like the pneumococcus,
produce pore-forming toxins with pro-oxidative
properties.35
Interestingly, cigarette smoking has been re-
ported to be an independent risk factor for serious
pneumococcal infection, the relative risk being
directly related to the extent of the smoking
habit.36 Cigarette smoking also causes inactivation
of API in the airways,37 an effect, which in the light
of the observations of the current study, may
contribute to the increased risk of invasive pneu-
mococcal disease in smokers. In this setting, the
interactive inhibitory effects of exposure to cigar-
ette smoke and pneumolysin may severely compro-
mise the cytoprotective, anti-inflammatory and
proposed antimicrobial activities of API in the
airways.14–16
It is noteworthy that oxidized API per se pos-
sesses proinflammatory properties by promoting
neutrophil migration,38 and activating the produc-
tion of reactive oxidants, chemokines and cytokines
by macrophages,39 which may further exacerbate
inflammatory damage to airway epithelium. Pneu-
mococcal disease is therefore likely to be accom-
panied by a multi-pronged assault on respiratory
epithelium mediated directly by the pneumococcal
cytotoxins pneumolysin and hydrogen peroxide,
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acting in concert with excessive amounts of
phagocyte-derived elastase and reactive oxidants
generated by pneumolysin-orchestrated, over-exu-
berant inflammatory responses.
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